Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years

Why It Matters

The expanded revenue outlook and strategic acquisitions position BioMarin to capture a larger share of the rare‑disease market, while strong cash generation reduces execution risk for its growing product portfolio.

Key Takeaways

• Q1 2026 revenue hits $766M, beating expectations.
• Full-year 2026 revenue forecast raised to $3.825‑$3.925B, 20% growth.
• FDA approves PALYNZIQ for adolescent phenylketonuria.
• $3.7B non‑convertible debt finances Amicus acquisition.
• Operating cash flow $221M; cash reserves $2B back pipeline.

Pulse Analysis

BioMarin’s latest earnings underscore a pivotal moment for the rare‑disease sector, where demand for specialty therapies outpaces supply. By integrating Amicus Therapeutics, BioMarin not only broadens its genetic‑medicine portfolio but also gains access to promising pipeline candidates that complement existing enzyme‑replacement drugs. This strategic move, combined with a robust 20% revenue uplift forecast, signals the company’s ability to scale commercially while navigating the high‑cost development landscape typical of orphan drugs.

Clinical momentum is another catalyst for BioMarin’s growth narrative. The FDA’s approval of PALYNZIQ expands treatment options for phenylketonuria, a condition with limited therapeutic choices, while the pending sNDA for VOXZOGO could unlock full market authorization for achondroplasia. Positive data from BMN 351 and VOXZOGO further de‑risk the pipeline, positioning BioMarin to deliver incremental sales as Phase 3 readouts emerge later this year. These developments enhance the company’s credibility among physicians and payers, potentially accelerating adoption rates.

From a financial perspective, BioMarin’s $3.7 billion non‑convertible debt issuance provides the capital needed for the Amicus deal without diluting shareholders. Coupled with $221 million of operating cash flow and a $2 billion cash cushion, the firm maintains a solid liquidity profile to fund R&D and commercial expansion. The market’s undervaluation perception may stem from short‑term earnings volatility, yet the combination of strong cash generation, strategic acquisitions, and a deepening pipeline suggests a compelling upside for investors with a two‑year horizon.